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Abstract
Background: Although the socioeconomic burden of 2009 pandemic influenza A (H1N1) was considerable, no reliable
estimates have been reported. Our aim was to compared medical costs and socioeconomic burden resulting from pandemic
influenza A (H1N1) 2009 with that of previous seasonal influenza.
Methods: We estimated the medical costs and socioeconomic burden of influenza from May 2007 to April 2010. We used
representative national data sources(data from the Health Insurance Review Agency, the National Health Insurance
Corporation, the Korea Centers for Disease Control and Prevention, and the Korean National Statistics Office) including
medical utilization, prescription of antivirals, and vaccination. Uncertainty of data was explored through sensitivity analysis
using Monte Carlo simulation.
Results: Compared with the seasonal influenza, total medical costs (US$291.7 million) associated with pandemic (H1N1)
2009 increased more than 37-fold. Compared with the 2007–2008 season, outpatient diagnostic costs (US$135.3 million)
were 773 times higher in the 2009–2010 season, and the mean diagnostic cost per outpatient visit was 58.8 times higher.
Total socioeconomic burden of pandemic (H1N1) 2009 was estimated at US$1581.3 million (10%–90%: US$1436.0–1808.3
million) and those of seasonal influenza was estimated at US$44.7 million (10%–90%: US$32.4–57.9 million) in 2007–2008
season and US$42.3 million (10%–90%: US$31.5–53.8 million) in 2008–2009 season. Indirect costs accounted for 56.0% of
total costs in pandemic (H1N1) 2009, and 66.48–68.09% in seasonal influenza. The largest contributors to total burden were
productivity losses of caregiver in pandemic (H1N1) 2009, and productivity losses due to morbidity of outpatient in seasonal
influenza.
Conclusions: In the Republic of Korea, socioeconomic burden of pandemic (H1N1) 2009 were considerably higher than
burden of the previous two influenza seasons, primarily because of high diagnostic costs and longer sick leave.
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Introduction
After the first cases of swine-origin influenza A were described
in Mexico and the United States in April 2009, pandemic
influenza A (H1N1) 2009 spread throughout the world. [1,2] The
first case of pandemic (H1N1) 2009 in the Republic of Korea
(ROK) was identified in a person returning from Mexico on May
2, 2009, and virus activity subsequently increased rapidly. [3–6].
Because of the high rates of incidence, the medical costs of
pandemic (H1N1) 2009 have been considerable. [7–9] In order to
prevent the spread of pandemic (H1N1) 2009, the government was
not performed only the health policy, such as quarantine, isolation,
and campaign for hygiene, but also the government was
responsible for stockpiling antivirals and developing and produc-
ing vaccines. [3,10] Pandemic (H1N1) 2009 would become a
significant burden in both healthcare and socioeconomic system.
On the other hands, the government was conducted surveil-
lance system for investment the scale occurred influenza.
However, the surveillance may have been under-reporting,
because the surveillance was included serological confirmed
patients. Therefore, efforts are needed to estimate the exact
socioeconomic burden of pandemic (H1N1) 2009.
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Although several studies have been conducted to estimate
disease the burden or medical costs of pandemic (H1N1) 2009,
these studies focused on disease severity, effective vaccination, or
community mitigation strategies. [11–16] Due to limitations of
representative national statistics, estimation on economic impact of
pandemic (H1N1) 2009 has not been conducted.
The purpose of this study was to determine the socioeconomic
burden of seasonal influenza (2007–2008 [May 2007 to April
2008] and 2008–2009 seasons [May 2008 to April 2009]) and
pandemic (H1N1) 2009 (2009–2010 influenza season [May 2009
to April 2010]) in the ROK and to compare medical costs and
socioeconomic burden of pandemic (H1N1) 2009 with those of
seasonal influenza.
Methods
Data Sources
Medical Care Utilization Data. Medical care utilization
data (e.g., date clinic/hospital visit, medical service, and cost per
service) were obtained from the Health Insurance Review &
Assessment Service (HIRA). (Table 1) All legal residents of the
ROK are covered by the National Health Insurance program,
which uses a fee-for-service payment system to reimburse
healthcare providers. [17] The Korean government regulates
these fees, and HIRA has the authority to review healthcare
insurance claims and assess healthcare quality. We selected all
insurance claims in which influenza was diagnosed (International
Classification of Diseases, 10th Revision, Clinical Modification
[ICD-10-CM] codes: J09–J11) between May 2007 and April 2010.
Monitoring of stockpiled antivirals. Before 2009–2010
season, because few antivirals for influenza were on the market in
the ROK due to rare prescriptions, almost all antivirals for
pandemic (H1N1) 2009 were stockpiled and managed by the
government in 2009–2010 season. Since August 21, 2009, the
Korea Centers for Disease Control and Prevention (KCDC) and
National Health Insurance Corporation have monitored daily
prescription of antivirals for influenza. [5].
Mortality Data. Death certificate data from the Korean
Statistical Information Service (KOSIS) were used to determine
influenza mortality (ICD-10-CM: J09–J11) for seasonal influenza
during 2007–2009. [18] The KCDC began active surveillance of
pandemic (H1N1) 2009-related mortality from August 15, 2009
(date of the first fatality), and a fatal case was defined as a person
with pandemic (H1N1) 2009, confirmed by ante-mortem or post-
mortem specimens, who died from a clinically compatible illness
or complications attributable to that infection. In 2009–2010
season, we used surveillance data from KCDC from August 15,
2009 until April 30, 2010.
Estimating Cost of Illness
The socioeconomic burden of influenza was estimated as direct
costs, indirect costs, and costs associated with prevention strategies.
To compare the socioeconomic burden of seasonal influenza in the
2007–2008 and 2008–2009 seasons with that of pandemic (H1N1)
2009, all resource utilization estimates were obtained for 2009 and
expressed in 2009 United States dollars (US$) using the 2009
average exchange rate (US$1= 1276.4 Korean won; Bank of
Korea).
Direct Costs. Direct healthcare costs consisted of medical
services and medication. Total medical costs associated with
influenza(ICD-10-CM codes: J09–J11) were obtained by adding
costs reported by all clinics and hospitals to HIRA for each season.
Non-stockpile antivirals and other drug costs were included in
medication costs reported by HIRA. Because stockpiled antivirals
were provided for free only in the 2009–2010 season, cost of
stockpiled antivirals was estimated as the cost of each drug
multiplied by the total number of prescriptions.
Direct non-healthcare costs consisted of transport costs related
to clinic or hospital visits. Transport costs were estimated by
multiplying the total number of clinic visits by the return fare,
reported by the 2005 Korean National Health and Nutrition
Examination Survey. [19] To estimate the cost of return fares, the
healthcare component of the Korean Consumer Price Index was
used to adjust costs to the 2009 values.
Indirect Costs. Indirect costs resulting from productivity
losses were estimated as: 1) productivity losses due to morbidity, 2)
productivity losses of caregiver, and 3) premature mortality
resulting from influenza. Indirect costs were estimated using a
human capital approach by multiplying expected mean earnings
by time lost at work and adjusted by the employment-population
ratio by matching gender and age.
Productivity losses of adults (20–64 years old) were estimated
from the average earnings in the general population (adjusted by
the employment–population ratio) by matching gender and age.
[18] For inpatients, we multiplied average daily earnings by
hospitalization day. For outpatients, we multiplied average daily
earnings by sick leave duration based on the first outpatient visit.
Subsequent outpatient visits were assumed to be follow-up
appointments for influenza, and work loss was estimated as a half
day. For calculating the outpatients productivity losses, sick leave
of outpatients (range: 0.5–4.5 days) was assumed according
previously published data for the 2007–2008 and 2008–2009
seasons. [20,21] For the 2009–2010 season, we surveyed patients
with laboratory-confirmed pandemic (H1N1) 2009 between
August 2009 and February 2010 in four university-based
quarantine hospitals (representing four provinces in the ROK).
The survey asked, ‘‘How many days of sick leave did you take to
stay home with influenza?’’ We mailed questionnaires to 10,833
patients in February and May 2010, and 2,166 patients (20.0%)
responded. Median sick leave of patients was 7 days (range: 1–28).
Unless they were admitted to the hospital, we assumed that
children #19 years and adults $65 years required care from a
family member, and that most caregivers were women. Caregiver
productivity losses were calculated by multiplying the time
required to care for a sick family member by average daily
earnings.
Lost earnings due to premature mortality were calculated from
the number of influenza-related deaths and the annual earnings of
those patients. Only patients ,65 years old (standard retirement
age) were included in this analysis. The expected future loss of
earnings due to premature mortality was adjusted using a 5%
discount rate. Life expectancy, average annual earnings, and
employment–population ratio by age and gender were based on
2009 general population data from the KOSIS. [18].
Prevention Strategy. Costs associated with prevention strat-
egies (national budget for influenza prevention and use of
protective equipment) were estimated only for the 2009–2010
season, because complete data were not available for the other
seasons. Data for execution of the budget regarding pandemic
(H1N1) 2009 (quarantine facilities, vaccine development, vaccine/
antiviral stockpiles) were obtained from the Korean National
Assembly Budget office. [22] Direct costs consisted of the cost of
stockpiled antivirals based on the actual usage; costs associated
with used stockpiled antivirals were excluded for estimating of the
costs associated with prevention strategies. The cost of protective
equipment (e.g., masks, hand sanitizers) was calculated by
multiplying purchase price by the probability of purchasing
(estimated as 32.5%), based on a survey. [23] Direct and indirect
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influenza-related costs were based on the target population
(patients), however prevention costs were based on the entire
population.
Statistical Analysis
Total costs were defined as the sum of direct costs, indirect costs,
and costs associated with prevention strategies. Data were
compared by chi-square test or one-way analysis of variance to
determine differences in medical costs across seasons. While
available national data such as medical costs and cost of
antiviral was used as fixed values, some data such as transport
costs and duration of sick leave, used as assumed value.
Therefore, uncertainty of the assumed data was explored through
probabilistic sensitivity analysis (1,000 independent simulation
trials) using Monte Carlo simulation (Oracle Crystal Ball, version
11.1.1.30, Oracle Corporation). the Monte Carlo simulation
assumed normal distribution for transport costs (mean 6 standard
deviation; inpatients: 19.1661.916, outpatients: 15.4761.547),
uniform distribution of sick leave days for seasonal influenza
(range: 0.5–4.5) in 2007–2008 and 2008–2009 seasons, and
negative binomial distribution for sick leave associated with
pandemic (H1N1) 2009 (probability = 0.7166, shape = 5), which
was fitted to questionnaire data. (see Table 1 for more details on
parameters and distribution of assumption factor).
Table 1. Parameter and data sources.
parameter
Distribution of assumption
factors* Data source
Seasonal influenza
(2007–2009
Seasons)
H1N1 Influenza
2009 (2009–2010
Season)
Direct costs
Direct medical costs
Medical costs of inpatient and
outpatient
Total medical cost HIRA data HIRA data
Stockpile antivirals Total cost of antiviral - NHIC data
Direct non-medical costs
Transport costs of inpatient Number of visits to inpatient HIRA data HIRA data
Return fare Normal (Mean = 19.2, SD = 1.92) KNHNES KNHNES
Transport costs of outpatient Number of visits to outpatient HIRA data HIRA data
Return fare Normal (Mean = 15.5, SD = 1.55) KNHNES KNHNES
Indirect costs
Productivity losses due to morbidity
of inpatient
Number of visits to inpatient &
Duration of hospitalization
HIRA data HIRA data
Average daily earnings &
Employment-population ratio
KOSIS data KOSIS data
Productivity losses due to morbidity
of outpatient
Number of visits to outpatient HIRA data HIRA data
Duration of sick leave Seasonal influenza: Uniform (Range:
0.5–4.5); H1N1 Influenza 2009:
Negative binomial (Probability
= 0.7166, Shape = 5)
Literature review Mailing survey
Average daily earnings &
Employment-population ratio
KOSIS data KOSIS data
Productivity losses of caregiver Duration of sick leave Seasonal influenza: Uniform (Range:
0.5–4.5); H1N1 Influenza 2009:
Negative binomial (Probability
= 0.7166, Shape = 5)
Literature review Mailing survey
Female average daily earnings
& Employment-population ratio
KOSIS data KOSIS data
Productivity losses due to premature
mortality
Mortality data KOSIS data KCDC surveillance
data
Life expectancy & Average
annual earnings
KOSIS data KOSIS data
Prevention strategy
Execution of the budget Execution of the budget
regarding pandemic (H1N1) 2009
- KNAB
Protective equipment Price of prevention equipment Uniform (Range: 0.47–4.7) - Literature review
Probability of purchasing Normal (Mean = 0.325, SD= 0.03) - Literature review
*Uncertainty of the data was explored through probabilistic sensitivity analysis using Monte Carlo simulation.
doi:10.1371/journal.pone.0084121.t001
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Results
During the 2009–2010 season (week 17, 2009 through week 16,
2010), a total of 266 fatal cases were reported (Figure 1).
Outpatient visits and antiviral prescriptions peaked at week 43.
Vaccinations against pandemic (H1N1) 2009 began on October
27, 2009, when the number of outpatient visits peaked (746,290/
week).
Inpatient visits during the 2009–2010 season (123,035)
increased 15- to 20-fold compared with two previous seasons,
and outpatient visits (4,609,026) increased 10-fold (Table 2). The
number of visits per person during the 2009–2010 season was not
increased compared with two previous seasons. During the 2009–
2010 season, total medical costs of inpatients increased 20-fold and
those costs of outpatients increased 50-fold. In both inpatient and
outpatient, the medical costs of all subcategory during the 2009–
2010 season increased compared with two previous seasons. The
proportion of each subcategory among inpatient medical costs was
not different among seasons (P-value = 0.598); whereas, the
proportion of each subcategory among outpatient differed
significantly (P-value ,0.001). The mean cost per visit differed
significantly across seasons for both inpatients and outpatients.
Among the subcategory of medical cost, the mean diagnostic cost
per visit in the 2009–2010 season was significantly increased
compared with two previous seasons.
We estimated the socioeconomic costs of influenza consisted of
direct costs (direct medical and non-medical costs), indirect costs
(productivity losses of morbidity, caregiver, and premature
mortality), and costs associated with prevention strategies (execu-
tion of the budget and protective equipment) (Table 3). We varied
the return fare for outpatients and inpatients, the duration of sick
leave, and the probability of purchasing and the price of
preventative equipment. Based on results of the Monte Carlo
simulation, the socioeconomic burden for pandemic (H1N1) 2009
was estimated at US$1,581.3 million, and those of seasonal
influenza were US$44.7 million in 2007–2008 season and US$42.3
million in 2008–2009 season. Indirect costs were the largest
proportion of total costs. In 2009–2010 season, 56.0% of total
costs were indirect costs, consisting primarily of productivity losses
of caregivers (30.0%) and morbidity (outpatient: 24.3%, inpatient
0.62%). In 2007–2008 and 2008–2009 seasons, the cost of
productivity losses due to morbidity was the largest component.
Discussion
Inpatient visits, outpatient visits, and total medical costs
increased significantly in the 2009–2010 season compared to two
previous seasons in the ROK. The 2009–2010 medical costs
(US$291.7 million) accounted for 1.24% of the 2009 total national
healthcare expenditures (US$23.48 billion). In contrast, 2007–
2008 medical costs (US$7.17 million) accounted for only 0.04% of
2007 national healthcare expenditures (US$19.25 billion), and
2008–2009 medical costs (US$7.90 million) were about 0.04% of
2008 national healthcare expenditures (US$20.67 billion). These
findings demonstrate the significance of pandemic (H1N1) 2009 as
a major public health concern in the ROK. [24].
Figure 1. Outbreak of Pandemic Influenza A (H1N1) 2009 and Main Response Strategy in Korea.
doi:10.1371/journal.pone.0084121.g001
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Compared with the 2007–2008 season, outpatient diagnostic
costs were 773 times higher in the 2009–2010 season, and the
mean diagnostic cost per outpatient visit was 58.8 times higher. In
addition to the increased number of influenza cases, the higher
medical costs during the 2009–2010 season may be due to the
increased use of diagnostic tests including real-time reverse
transcriptase-polymerase chain reaction (RT-PCR). Although
laboratory tests can confirm influenza cases, clinical judgment by
physicians is important in the identification of influenza. On
October 30 (week 43) 2009, the government recommended
antivirals administration who met the case definition of influen-
za-like illness, without laboratory confirmation. However, diag-
nostic costs did not decrease after that time.
Besides public fears about the pandemic, other factors may be
associated with the increased diagnostic testing. First, in the ROK,
medical cost consist those covered by insurer and those covered by
patients (coinsurance) due to the National Health Insurance
program. Before March 2010, the National Health Insurance
program covered 40–50% of the cost for RT-PCR testing,
suggesting overutilization of these tests because they were relatively
inexpensive for the patient. After March 2010(week 11), the
patient covered up to 100% of real-time RT-PCR costs,
decreasing its proportion of diagnostic costs. Second, most schools
and workplaces required negative diagnostic test results for
suspected cases during the pandemic, despite government
recommendations. Therefore, suspected cases visited clinics and
were examined laboratory tests to obtain a medical certificate and
not to get treatment. The medical cost breakdown did not differ
significantly among age groups, suggesting that age groups not
incurred greater diagnostic costs (data not shown).
In this study, total 2009–2010 socioeconomic costs (US$1,581.3
million) accounted for 0.19% of the 2009 gross domestic product
(US$832.9 billion). In contrast, total 2007–2008 socioeconomic
costs (US$44.7 million) accounted for only 0.005% of the 2008
gross domestic product. In the 2007–2008 and 2008–2009
seasons, indirect costs were the largest proportion of total costs.
Specifically, 56.0% of 2009–2010 costs were indirect costs,
consisting primarily of productivity losses of caregivers (30.0%)
and adult outpatients (24.3%). In the pandemic’s early stage,
public health officials recommended that students and employees
with influenza rest at home for a week, whereas the mean sick
leave was ,1 to 4.3 days for typical seasonal influenza. [20,25]
Table 2. Number of Visits and Medical Costs for Influenza in the Republic of Korea, 2007–2010.
2007–2008 Season 2008–2009 Season 2009–2010 Season P-value*
Total number of visits
Inpatients 6,502 8,775 123,035
Outpatients 446,713 404,623 4,609,026
Number of visits per person{
Inpatients 1.0760.28 1.0560.22 1.0660.25
Outpatients 1.8462.26 1.7562.10 1.4561.07
Medical costs (thousand US$)
Inpatients
Total costs 2,740.4 (100.0) 3,799.3 (100.0) 77,004.9 (100.0)
Consultation costs 1,358.0 (49.6) 1,924.8 (50.7) 34,359.8 (44.6) 0.598
Diagnostic costs 513.1 (18.7) 717.2 (18.9) 20,872.1 (27.1)
Medication and other costs 869.2 (31.7) 1,157.4 (30.5) 21,773.0 (28.3)
Outpatients
Total costs 4,428.9 (100.0) 4,102.7 (100.0) 214,649.0 (100.0)
Consultation costs 3,897.4 (88.0) 3,544.2 (86.4) 55,542.1 (25.9) ,0.001
Diagnostic costs 175.0 (4.0) 205.0 (5.0) 135,313.9 (63.0)
Medication and other costs 356.6 (8.1) 353.5 (8.6) 23793.0 (11.1)
Costs per visit (US$){
Inpatients
Total costs 421.46422.75 432.96411.83 625.86800.81 ,0.001
Consultation costs 208.86213.38 219.36190.71 279.26356.30 ,0.001
Diagnostic costs 78.96105.86 81.76103.78 169.66190.50 ,0.001
Medication and other costs 133.76145.33 131.96173.53 176.96347.68 ,0.001
Outpatients
Total costs 9.967.53 10.169.10 16.6656.32 ,0.001
Consultation costs 8.764.16 8.863.74 12.069.54 ,0.001
Diagnostic costs 0.463.65 0.565.32 29.4641.64 ,0.001
Medication and other costs 0.862.35 0.963.37 5.2621.17 ,0.001
*P-values for proportional difference of subcategories of medical costs across seasons were determined by chi-square tests, and P-values for mean difference of costs
per visit across seasons were determined by analysis of variance.
{Results are expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0084121.t002
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This longer sick leave may have contributed to the high indirect
costs for pandemic (H1N1) 2009.
The ROK has several national surveillance systems including
pneumonia and influenza surveillance and sentinel surveillance for
influenza-like illness known as the Korea Influenza Surveillance
Scheme. [9] However, the ROK does not have a hospital-based
surveillance system for emerging diseases, such as the Emerging
Infections Program in the United States, which collects data about
susceptibility, clinical course, treatment efficacy, and outcomes.
[26] Therefore, little information on these data was available in
the early stages of the pandemic in the ROK. Although the
severity of pandemic (H1N1) 2009 was similar to that of typical
seasonal influenza, early response strategies in the ROK (e.g.,
confirmation testing, social distancing) were not effectively
changed because of limited national data regarding clinical
characteristics.
Our study has some limitations. First, we could not include costs
incurred by asymptomatic patients or those not admitted to the
hospital in calculating influenza-related costs. We considered
preventative actions taken by the general population and
execution of the budget (including an improved response system)
and its promotion to the general population. Second, the rapid
antigen test for influenza was also widely used in the ROK.
However, the National Health Insurance Corporation did not
cover this test; therefore, we could not acquire data regarding its
use or include these costs in our analysis. Third, we estimated
outpatient sick leave based on the first clinic visit only and assumed
no recurrence or infection with other influenza strains. Therefore,
the diagnostic and productivity costs may also be underestimated.
In addition, misclassification and underreporting may affect our
study. When pneumonia occurs as a complication of influenza,
influenza cases may be coded as pneumonia (ICD-10-CM codes:
J12–J18). However, misclassification or underreporting of influ-
enza may have been lower in the 2009–2010 season (when
confirmation tests were widely used), resulting in overestimated
differences in medical costs. We found that the number of
pneumonia cases and fatal cases in the 2009–2010 season were
similar to numbers reported in previous seasons (Table S1).
Therefore, misclassification did not appear to have affected our
results. Mortality data were obtained from death certificates for
the 2007–2008 and 2008–2009 seasons. When several disease
codes can be used as cause of death, the most severe disease is
generally used on a death certificate. Therefore, influenza
mortality may be misclassified/underreported, underestimating
the costs of premature mortality. Because in 2009–2010 season the
KCDC mortality surveillance data was used, the costs of
premature mortality of 2009–2010 season could not compare
with those of previous season.
Because of this potential underestimation in influenza-associat-
ed costs, the true socioeconomic burden of pandemic (H1N1) 2009
may exceed our estimate. Although a conservative formula was
used, we found that total costs and average costs per visit of
pandemic (H1N1) 2009 were significantly higher than those of
typical seasonal influenza.
In conclusion, medical and socioeconomic costs of pandemic
(H1N1) 2009 were considerably higher than costs of the previous
two influenza seasons, primarily because of longer sick leave and
high diagnostic costs. Therefore, government policies such as risk
communication concerning sick leave and diagnostic testing could
be modified to reduce the socioeconomic burden in similar
situations. In addition, a surveillance system for clinical charac-
Table 3. Estimating Costs of Illness for Pandemic Influenza A (H1N1) 2009 and Seasonal Influenza in the Republic of Korea, 2007–
2010.
2007–2008 Season 2008–2009 Season 2009–2010 Season
Category Cost (million US$)
% total
costs Cost (million US$)
% total
costs Cost (million US$)
% total
costs
Direct costs
Direct medical costs
Medical costs of inpatients 2.74 6.16 3.80 8.90 77.00 4.79
Medical costs of outpatients 4.43 9.95 4.10 9.61 214.61 13.37
Stockpile antivirals NA NA NA NA 41.46 2.58
Direct non-medical costs
Transport costs of inpatients 0.12 (0.11–0.14) 0.28 0.17(0.15–0.19) 0.39 2.35 (2.04–2.65) 0.15
Transport costs of outpatients 6.91 (5.98–7.84) 15.53 6.23 (5.50–7.01) 14.61 71.16 (61.77–80.78) 4.43
Indirect costs (Productivity losses)
Productivity losses due to morbidity of
inpatient
0.60 1.35 0.62 1.46 9.93 0.62
Productivity losses due to morbidity of
outpatient
20.10(8.99–32.58) 45.16 18.31(7.86–28.98) 42.92 390.23 (281.16–499.30) 24.30
Productivity losses of caregiver 9.54(4.38–14.42) 21.43 9.32(4.22–14.52) 21.84 480.00(347.75–612.25) 29.89
Productivity losses due to premature mortality 0.07 0.15 0.11 0.26 19.16 1.19
Prevention strategy
Execution of the budget NA NA NA NA 259.26 16.15
Protective equipment NA NA NA NA 40.60 (14.50–68.85) 2.53
Total socioeconomic costs 44.65 (32.35–57.87) 100.00 42.31 (31.50–53.75) 100.00 1,581.27 (1435.96–1808.33) 100.00
NA: not available Costs are expressed as fixed value or median value (range, 10%–90%).
doi:10.1371/journal.pone.0084121.t003
Socioeconomic Burden of Influenza, 2007-2010
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e84121
teristics (e.g., susceptibility, treatment efficacy, adverse drug
reactions, and severity) in the early stages of an outbreak is needed.
Supporting Information
Table S1 Annual Medical Costs for Pneumonia (ICD-10-
CM: J12–J18) in the Republic of Korea, 2007–2010.
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